ResMed's Tariff Exemption Bolsters Competitive Position -- Market Talk

Dow Jones

Apr 28

0354 GMT - ResMed's exemption from U.S. tariffs supports the breath-tech provider's already strong competitive position, according to Morgans analyst Derek Jellinek. He tells clients in a note that the exemption is important, but that he already liked ResMed for its expanding U.S. manufacturing footprint, the emergence of new technologies driving adoption, and favorable trends in wearables and weight-loss drugs. Jellinek observes that growth in ResMed's U.S. mask sales continues to outpace that of the broader industry, with rest-of-world sales growth poised to eventually catch up. Morgans keeps an add rating on the stock and raises its target price 1.1% to A$44.07. Shares are up 2.6% at A$37.005.(stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 27, 2025 23:54 ET (03:54 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2530415685"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530415685\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530415685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-28 11:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530415685","market":"hk","top_or_hot":-1,"title":"ResMed's Tariff Exemption Bolsters Competitive Position -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0354 GMT - ResMed's exemption from U.S. tariffs supports the breath-tech provider's already strong competitive position, according to Morgans analyst Derek Jellinek. He tells clients in a note that the exemption is important, but that he already liked ResMed for its expanding U.S. manufacturing footprint, the emergence of new technologies driving adoption, and favorable trends in wearables and weight-loss drugs. Jellinek observes that growth in ResMed's U.S. mask sales continues to outpace that of the broader industry, with rest-of-world sales growth poised to eventually catch up. Morgans keeps an add rating on the stock and raises its target price 1.1% to A$44.07. Shares are up 2.6% at A$37.005.(stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2025 23:54 ET (03:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed's Tariff Exemption Bolsters Competitive Position -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed's Tariff Exemption Bolsters Competitive Position -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-28 11:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0354 GMT - ResMed's exemption from U.S. tariffs supports the breath-tech provider's already strong competitive position, according to Morgans analyst Derek Jellinek. He tells clients in a note that the exemption is important, but that he already liked ResMed for its expanding U.S. manufacturing footprint, the emergence of new technologies driving adoption, and favorable trends in wearables and weight-loss drugs. Jellinek observes that growth in ResMed's U.S. mask sales continues to outpace that of the broader industry, with rest-of-world sales growth poised to eventually catch up. Morgans keeps an add rating on the stock and raises its target price 1.1% to A$44.07. Shares are up 2.6% at A$37.005.(stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2025 23:54 ET (03:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2008162690.USD","symbol_name":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2530415685","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530415685","pubTimestamp":1745812440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0354 GMT - ResMed's exemption from U.S. tariffs supports the breath-tech provider's already strong competitive position, according to Morgans analyst Derek Jellinek. He tells clients in a note that the exemption is important, but that he already liked ResMed for its expanding U.S. manufacturing footprint, the emergence of new technologies driving adoption, and favorable trends in wearables and weight-loss drugs. Jellinek observes that growth in ResMed's U.S. mask sales continues to outpace that of the broader industry, with rest-of-world sales growth poised to eventually catch up. Morgans keeps an add rating on the stock and raises its target price 1.1% to A$44.07. Shares are up 2.6% at A$37.005.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","RMD":"瑞思迈","RMD.AU":"Resmed DRC","BK4548":"巴美列捷福持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4082":"医疗保健设备","BK7007":"医疗保健设备","BK4504":"桥水持仓","BK7501":"新冠治疗股","BK4588":"碎股"},"translate_title":"瑞思迈的关税豁免增强了竞争地位——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"RMD.AU":0.9},"content_text":"0354 GMT - ResMed's exemption from U.S. tariffs supports the breath-tech provider's already strong competitive position, according to Morgans analyst Derek Jellinek. He tells clients in a note that the exemption is important, but that he already liked ResMed for its expanding U.S. manufacturing footprint, the emergence of new technologies driving adoption, and favorable trends in wearables and weight-loss drugs. Jellinek observes that growth in ResMed's U.S. mask sales continues to outpace that of the broader industry, with rest-of-world sales growth poised to eventually catch up. Morgans keeps an add rating on the stock and raises its target price 1.1% to A$44.07. Shares are up 2.6% at A$37.005.(stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2025 23:54 ET (03:54 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}